Teijin Pharma Ltd. and NovAliX SAS have entered into a multi-target drug discovery collaboration to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise and technology platforms to identify chemotypes, and then use its native nano-MS technology for further characterization of selected small molecule hit structures. NovAliX will receive technology access fees as well as further research funding. Fi...